{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:46:14Z","timestamp":1775893574273,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jneuroim.2017.06.012","type":"journal-article","created":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T02:47:59Z","timestamp":1498877279000},"page":"91-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis"],"prefix":"10.1016","volume":"310","author":[{"given":"Sonia","family":"Villani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nunzia","family":"Zanotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Ambrogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manola","family":"Comar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Franciotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Dolci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Cason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalia","family":"Ticozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3199-9369","authenticated-orcid":false,"given":"Serena","family":"Delbue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2017.06.012_bb0005","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1073\/pnas.91.15.7144","article-title":"Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells","volume":"91","author":"Adams","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039794","article-title":"Expression of Ccl11 associates with immune response modulation and protection against neuroinflammation in rats","volume":"7","author":"Adzemovic","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0015","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/33340","article-title":"Chemokines and leukocyte traffic","volume":"392","author":"Baggiolini","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0020","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1073\/pnas.0912437107","article-title":"Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells","volume":"107","author":"Benkhoucha","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0025","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jmv.22004","article-title":"A molecular case-control study of the Merkel cell polyomavirus in colon cancer","volume":"83","author":"Campello","year":"2011","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0030","doi-asserted-by":"crossref","first-page":"901312","DOI":"10.1155\/2015\/901312","article-title":"Epstein-Barr virus specific antibody response in multiple sclerosis patients during 21 months of natalizumab treatment","volume":"2015","author":"Castellazzi","year":"2015","journal-title":"Dis. Markers"},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0165-5728(99)00002-8","article-title":"IL-7 enhances Ag-specific human T cell response by increasing expression of IL-2R alpha and gamma chains","volume":"96","author":"Chou","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0040","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/jlb.67.6.757","article-title":"Interleukin-16","volume":"67","author":"Cruikshank","year":"2000","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0045","first-page":"51","article-title":"A case of a progressive multifocal leukoencephalopathy patient with four different JC virus transcriptional control region rearrangements in cerebrospinal fluid, blood, serum, and urine","volume":"11","author":"Delbue","year":"2005","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0050","first-page":"645","article-title":"JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients","volume":"21","author":"Delbue","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0055","article-title":"JC virus infection is acquired very early in life: evidence from a longitudinal serological study","author":"Elia","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1034\/j.1600-0404.2000.101002095.x","article-title":"IL-1ra serum levels in disease stages of MS\u2014a marker for progression?","volume":"101","author":"Heesen","year":"2000","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pharmthera.2004.11.007","article-title":"Cytokines in multiple sclerosis: from bench to bedside","volume":"106","author":"Imitola","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0070","doi-asserted-by":"crossref","first-page":"7196","DOI":"10.4049\/jimmunol.0901404","article-title":"Alpha4beta1 integrin mediates the recruitment of immature dendritic cells across the blood-brain barrier during experimental autoimmune encephalomyelitis","volume":"184","author":"Jain","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1468-1331.2007.02037.x","article-title":"Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis","volume":"15","author":"Khademi","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0080","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1468-1331.2009.02532.x","article-title":"The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers","volume":"16","author":"Khademi","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0085","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1212\/WNL.0b013e3181a8266f","article-title":"Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells","volume":"72","author":"Kivisakk","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0090","series-title":"Robbins and Cotran. Pathologic Basis of Disease","author":"Kumar","year":"2005"},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0095","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.bcp.2006.06.014","article-title":"New approaches to blockade of alpha4-integrins, proven therapeutic targets in chronic inflammation","volume":"72","author":"Kummer","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/400_2008_12","article-title":"Potential triggers of MS","volume":"51","author":"Libbey","year":"2010","journal-title":"Results Probl. Cell Differ."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0105","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1177\/1352458514532700","article-title":"Interferon beta treatment of multiple sclerosis increases serum interleukin-7","volume":"20","author":"Lundstrom","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/1352458509355068","article-title":"Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid","volume":"16","author":"Mellergard","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0115","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clineuro.2004.02.008","article-title":"Bio-markers of disease activity and response to therapy in multiple sclerosis","volume":"106","author":"Miller","year":"2004","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jneuroim.2012.06.008","article-title":"Cerebrospinal hepatocyte growth factor levels correlate negatively with disease activity in multiple sclerosis","volume":"251","author":"Muller","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0125","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/ane.12215","article-title":"Interferon beta-1a reduces increased interleukin-16 levels in multiple sclerosis patients","volume":"130","author":"Nischwitz","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0130","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1352458513505353","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","volume":"20","author":"Outteryck","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0135","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0140","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1177\/1352458515599681","article-title":"Anti-JC virus antibody titres increase over time with natalizumab treatment","volume":"21","author":"Raffel","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0145","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10875-011-9522-x","article-title":"Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism","volume":"31","author":"Ramos-Cejudo","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0150","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1034\/j.1600-065X.2002.18611.x","article-title":"Alpha4 integrins and the immune response","volume":"186","author":"Rose","year":"2002","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0155","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"Sawcer","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0160","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","article-title":"Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis","volume":"325","author":"Sharief","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0165","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.4103\/1673-5374.165294","article-title":"Chemotactic signaling and beyond: link between interleukin-16 and axonal degeneration in multiple sclerosis","volume":"10","author":"Skundric","year":"2015","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0170","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev.neuro.25.112701.142913","article-title":"Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy","volume":"25","author":"Steinman","year":"2002","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1527-3458.2007.00003.x","article-title":"Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases","volume":"13","author":"Stuve","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128952","article-title":"Plasma biomarkers discriminate clinical forms of multiple sclerosis","volume":"10","author":"Tejera-Alhambra","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0185","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1034\/j.1600-0404.2002.01125.x","article-title":"Hepatocyte growth factor in cerebrospinal fluid in neurologic disease","volume":"106","author":"Tsuboi","year":"2002","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2017.06.012_bb0190","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572817301108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572817301108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:30:17Z","timestamp":1759048217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572817301108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":38,"alternative-id":["S0165572817301108"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2017.06.012","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2017.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}